GlassScriptPhysician profile
Abigail Skene
NPI 1235745803
$5,811.36
in general payments reported to CMS, 2019-2025
26 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $631 · 2023: $1,975 · 2024: $2,011 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,894 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,893.50 |
| Education | $286.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $899.02 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $835.74 | 2022-2025 | Caplyta |
| Alkermes, INC. | $592.51 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $497.31 | 2022-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $433.24 | 2022-2024 | Ingrezza |
| Abbvie INC. | $427.99 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $351.55 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Bausch Health US, LLC | $248.64 | 2022-2024 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $242.29 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $236.37 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $198.94 | 2023-2024 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $175.83 | 2022-2025 | Fanapt, Hetlioz |
| Corium, LLC | $93.75 | 2023-2024 | Azstarys |
| Sage Therapeutics, LLC | $89.80 | 2022-2025 | Zurzuvae |
| Eisai INC. | $66.52 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $62.01 | 2022-2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $58.26 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $52.75 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $46.46 | 2023 | Quviviq |
| Novo Nordisk INC | $42.05 | 2023-2025 | Wegovy |
| Almatica Pharma LLC | $39.38 | 2024-2025 | Loreev Xr |
| Biogen, INC. | $38.81 | 2025 | Leqembi |
| Neos Therapeutics, LP | $29.76 | 2023-2024 | Adzenys Xr-Odt |
| Avadel Cns Pharmaceuticals, LLC | $19.71 | 2024 | Lumryz |
| Noven Therapeutics, LLC | $19.03 | 2022 | |
| Indivior INC. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Skene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.